News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
Wholly owned subsidiary of Alif Holding to focus on maritime protection, smart ports, underwater intelligence and critical infrastructure protection; Dr. Jasem Al-Mansory expected to serve as ChairmanABU DHABI, UAE,
ServiceTitan (TTAN) stock drops premarket despite Q2 earnings beat as weak Q3 revenue guidance & a CRO transition weigh on sentiment.
Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants who were randomized
Einride's autonomous driving technology, Einride Driver, and AI-powered freight intelligence platform will help defense organizations move supplies through contested environments. The partnership with UNIQAI will
Flotek Industries (NYSE:FTK) raises FY2026 sales outlook from $340.000 million-$350.000 million to $360.000 million-$370.000 million vs $344.598 million estimate.
Cooper Companies will report Q3 earnings Sept. 9; analysts expect EPS of $1.12 and revenue of $1.10B.
CGI (TSX:GIB) (NYSE:GIB), one of the world's largest independent technology and professional services firms, today announced the acquisition of Callibrity, strengthening CGI's presence in Cincinnati and
BMO Capital analyst Kelly Crago initiates coverage on Deckers Outdoor (NYSE:DECK) with a Underperform rating and announces Price Target of $70.
Kim Fennebresque named Lead Independent DirectorWhitman brings over 40 years of business, technology and strategic innovation experience to Albertsons Cos. as the retailer embarks on a defining period in its
Filed: 2026-09-09 AccNo: 0001104659-26-106101 Size: 278 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) from Neutral to Neutral.
Filed: 2026-09-09 AccNo: 0001646972-26-000054 Size: 163 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Filed: 2026-09-09 AccNo: 0001627223-26-000027 Size: 21 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
– Reuters cites Iraqi port officials
Needham analyst Chris Pierce initiates coverage on Kodiak AI (NASDAQ:KDK) with a Buy rating and announces Price Target of $8.
– Reuters cites Iran Foreign Ministry statement
Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:TTAN) with a Buy and maintains $100 price target.
Scotts Miracle-Gro, Linde and Graphic Packaging are oversold materials stocks with RSI near 30, potentially offering undervalued buying opportunities.
SpaceX (SPCX) shares drop premarket amid a broader market slide. Get the latest analyst outlook, stock targets, and market updates.
ProLogium today announced a further deepening of its long-term strategic partnership with Kyushu Electric Power Co., Inc. (Kyushu Electric Power). Following ongoing collaboration across energy, next-generation batteries
BTIG analyst Nick Altmann reiterates ServiceTitan (NASDAQ:TTAN) with a Buy and maintains $110 price target.
JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE:JKS), today announced that its board of directors (the "Board") has approved a proposal to change the Company's English name
BTIG analyst Sam Eiber reiterates Neuronetics (NASDAQ:STIM) with a Buy and maintains $6 price target.
The award supports the continuity and readiness of essential national security systems. It reinforces KBR’s strategic position as a trusted technology partner, combining deep mission expertise with an outcome-driven
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary
These awards expand AEVEX’s support for operational requirements across high‑priority mission areas. Under these efforts, AEVEX will deliver one‑way attack systems and provide associated engineering, development, and
BTIG analyst Nick Altmann reiterates Braze (NASDAQ:BRZE) with a Buy and maintains $35 price target.
FEDERAL PERMITTINGKilbourne remains on track under the FAST-41 permitting schedule, with all federal permits targeted for issuance by no later than August 2027.Section 404 (Clean Water Act): U.S. Army Corps of Engineers